INmune Bio Inc. - Common stock (INMB): Price and Financial Metrics

INmune Bio Inc. - Common stock (INMB): $9.74

0.41 (-4.04%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add INMB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#345 of 357

in industry

INMB Price/Volume Stats

Current price $9.74 52-week high $14.74
Prev. close $10.15 52-week low $6.50
Day low $9.70 Volume 35,367
Day high $10.10 Avg. volume 103,996
50-day MA $10.71 Dividend yield N/A
200-day MA $9.84 Market Cap 192.68M

INMB Stock Price Chart Interactive Chart >


INmune Bio Inc. - Common stock (INMB) Company Bio


INmune Bio Inc., a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood. The company was founded in 2015 and is based in La Jolla, California.


INMB Latest News Stream


Event/Time News Detail
Loading, please wait...

INMB Latest Social Stream


Loading social stream, please wait...

View Full INMB Social Stream

Latest INMB News From Around the Web

Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers as we check out all of the most recent news for Tuesday morning!

William White on InvestorPlace | December 19, 2023

INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA

Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its timeline to successfully conclude the trial. In the US, the previously identified clinical hold issues have been successfully addressed however the Phase II study remains on clinical hold pending additional information on long-term stability which the Company will provide before the end of 2023. Boca R

Yahoo | December 18, 2023

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium

INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the tumor killing immunology of the tumor microenvironment. Boca Raton, Florida, Nov. 29, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is prese

Yahoo | November 29, 2023

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease

Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the patient’s innate immune system to combat disease, announced today it has received European Medicines Agency’s (EMA) Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM) in France and the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) in Spa

Yahoo | November 27, 2023

Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Yahoo | November 17, 2023

Read More 'INMB' Stories Here

INMB Price Returns

1-mo -17.25%
3-mo -16.03%
6-mo 1.35%
1-year 23.76%
3-year -28.17%
5-year -4.98%
YTD -13.50%
2023 77.60%
2022 -37.84%
2021 -40.77%
2020 196.90%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!